Zealand Pharma ASZLDPF 62 WACC % is 9.89% as of Jun. 26, 2026, which is 43% above its 10-year median of 6.92. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,920.24 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,428 Biotechnology companies, Zealand Pharma AS ranks better than 57.14% on this metric.
As of today (2026-06-26), Zealand Pharma AS's weighted average cost of capital is 9.89%%. Zealand Pharma AS's ROIC % is 1514.29% (calculated using TTM income statement data).
Zealand Pharma AS generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
For a comprehensive WACC calculation, please access the WACC Calculator.
Zealand Pharma AS (OTCPK:ZLDPF) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Zealand Pharma AS's weighted average cost of capital is 9.89%%. Zealand Pharma AS's ROIC % is 1514.29% (calculated using TTM income statement data).
Zealand Pharma AS generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
Zealand Pharma AS WACC % Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS WACC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's WACC % distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Zealand Pharma AS's market capitalization (E) is $3018.073 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Zealand Pharma AS's latest one-year quarterly average Book Value of Debt (D) is $62.0272 Mil.
a) weight of equity = E / (E + D) = 3018.073 / (3018.073 + 62.0272) = 0.9799
b) weight of debt = D / (E + D) = 62.0272 / (3018.073 + 62.0272) = 0.0201
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.888%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Zealand Pharma AS's beta is 1.1799.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.888% + 1.1799 * 6% = 9.9674%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Zealand Pharma AS's interest expense (positive number) was $4.117 Mil. Its total Book Value of Debt (D) is $62.0272 Mil.
Cost of Debt = 4.117 / 62.0272 = 6.6374%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 84.677 / 1071.679 = 7.9%.
Zealand Pharma AS's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.9799
*
9.9674%
+
0.0201
*
6.6374%
*
(1 - 7.9%)
=
9.89%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a WACC % of 9.89% as of Jun. 26, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Zealand Pharma AS and its competitors. This is 43% above median its historical median of 6.92. Over the past decade, Zealand Pharma AS's WACC % has ranged from 3.22 to 9.03. According to the industry distribution chart, Zealand Pharma AS ranks #612 out of 1428 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Zealand Pharma AS's WACC % too high?
Zealand Pharma AS's current WACC % of 9.89% is 43% above median its 10-year median of 6.92. Over the past 10 years, this metric has ranged from a low of 3.22 to a high of 9.03. The Biotechnology industry median WACC % is 10.03. Zealand Pharma AS's value of 9.89% is 1.3% below this industry median. Based on the distribution chart, Zealand Pharma AS ranks #612 out of 1428 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #612 out of 1428 companies for WACC %. This puts Zealand Pharma AS in the upper half of its industry. The industry median WACC % is 10.03. Zealand Pharma AS's value of 9.89% is 1.3% below this benchmark. Historically, Zealand Pharma AS's own WACC % has ranged from 3.22 to 9.03 over the past decade. While the company's 10-year median is 6.92 vs. the industry median of 10.03, Zealand Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current WACC % of 9.89% is 1.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median WACC % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current WACC % is 9.89%, which is 43% above median its own 10-year median of 6.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,920.24, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current WACC % is 9.89%, which is 43% above median its 10-year median of 6.92 and 1.3% below the Biotechnology industry median of 10.03. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current WACC % is 9.89% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,920.24.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
WACC %: 9.89% (43% above median its 10-year median of 6.92)
GF Value™: $1,920.24 vs. price of $42.89 (97.8% below fair value)
Industry Position: 1.3% below the Biotechnology median (#612 of 1428)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
